| scholarly article | Q13442814 |
| P6179 | Dimensions Publication ID | 1040933988 |
| P356 | DOI | 10.1186/S13550-016-0213-8 |
| P932 | PMC publication ID | 4936982 |
| P698 | PubMed publication ID | 27388754 |
| P50 | author | Elias Arnér | Q5360441 |
| Katarina Johansson | Q58825652 | ||
| Sharon Stone-Elander | Q87843604 | ||
| P2093 | author name string | Stig Linder | |
| Li Lu | |||
| Maria Hägg Olofsson | |||
| Stefan Ståhl | |||
| Qing Cheng | |||
| Helena Wållberg | |||
| Jan-Olov Thorell | |||
| Hanna-Stina Martinsson Ahlzén | |||
| Jonas Grafström | |||
| Tetyana Tegnebratt | |||
| Sel-tag imaging project | |||
| P2860 | cites work | In situ quantification of HER2-protein tyrosine kinase 6 (PTK6) protein-protein complexes in paraffin sections from breast cancer tissues | Q24294917 |
| Role of individual MARK isoforms in phosphorylation of tau at Ser²⁶² in Alzheimer's disease | Q24339611 | ||
| Quantitative in vivo cell-surface receptor imaging in oncology: kinetic modeling and paired-agent principles from nuclear medicine and optical imaging | Q27023605 | ||
| Combining [11C]-AnxA5 PET imaging with serum biomarkers for improved detection in live mice of modest cell death in human solid tumor xenografts | Q27329087 | ||
| Comparison of the biodistribution and tumor targeting of two 99mTc-labeled anti-EGFR nanobodies in mice, using pinhole SPECT/micro-CT. | Q39991878 | ||
| A model of human tumor dormancy: an angiogenic switch from the nonangiogenic phenotype | Q40310331 | ||
| Site-specifically 11C-labeled Sel-tagged annexin A5 and a size-matched control for dynamic in vivo PET imaging of protein distribution in tissues prior to and after induced cell death. | Q43711485 | ||
| Novel oncologic drugs: what they do and how they affect images. | Q44432450 | ||
| Measurement of potential doubling time for human tumor xenografts using the cytokinesis-block method | Q49125386 | ||
| Exploiting the 21st amino acid-purifying and labeling proteins by selenolate targeting. | Q51525547 | ||
| Comparison of methods for evaluating radiolabelled Annexin A5 uptake in pre-clinical PET oncological studies. | Q53054598 | ||
| Development of [(11)C]erlotinib positron emission tomography for in vivo evaluation of EGF receptor mutational status. | Q53133732 | ||
| Tagging recombinant proteins with a Sel-tag for purification, labeling with electrophilic compounds or radiolabeling with 11C. | Q54443867 | ||
| Steady-state blood volume measurements in experimental tumors with different angiogenic burdens a study in mice. | Q55473086 | ||
| Autofluorescence spectroscopy of rat liver during experimental transplantation procedure. An approach for hepatic metabolism assessment | Q59621094 | ||
| Graphical evaluation of blood-to-brain transfer constants from multiple-time uptake data | Q28274520 | ||
| Epidermal growth factor-related peptides and their receptors in human malignancies | Q28293442 | ||
| High-level expression in Escherichia coli of selenocysteine-containing rat thioredoxin reductase utilizing gene fusions with engineered bacterial-type SECIS elements and co-expression with the selA, selB and selC genes | Q28583566 | ||
| Direct observation of individual endogenous protein complexes in situ by proximity ligation | Q29616032 | ||
| Affinity maturation of a Taq DNA polymerase specific affibody by helix shuffling | Q30810400 | ||
| Phage display selection of Affibody molecules with specific binding to the extracellular domain of the epidermal growth factor receptor. | Q33282523 | ||
| Directed evolution to low nanomolar affinity of a tumor-targeting epidermal growth factor receptor-binding affibody molecule | Q33315521 | ||
| Accounting for pharmacokinetic differences in dual-tracer receptor density imaging. | Q33688285 | ||
| A modeling analysis of the effects of molecular size and binding affinity on tumor targeting | Q33835328 | ||
| An intracellular targeted antibody detects EGFR as an independent prognostic factor in ovarian carcinomas | Q33960748 | ||
| Positron emission tomography compartmental models | Q34327907 | ||
| EGFR and cancer prognosis | Q34399312 | ||
| PET of EGFR expression with an 18F-labeled affibody molecule | Q34429075 | ||
| Binding proteins selected from combinatorial libraries of an alpha-helical bacterial receptor domain | Q34435244 | ||
| Endocytosis and intracellular trafficking of ErbBs | Q34827744 | ||
| Imaging the dopamine system with in vivo [11C]raclopride displacement studies: understanding the true mechanism | Q36136737 | ||
| In vivo quantification of tumor receptor binding potential with dual-reporter molecular imaging | Q36479293 | ||
| Antibody tumor penetration: transport opposed by systemic and antigen-mediated clearance. | Q37187003 | ||
| Experimental results and related clinical implications of PET detection of epidermal growth factor receptor (EGFr) in cancer | Q37289600 | ||
| Characterization of membranous and cytoplasmic EGFR expression in human normal renal cortex and renal cell carcinoma | Q37363872 | ||
| Should we be surprised at the paucity of response to EGFR inhibitors? | Q37467394 | ||
| Micro-CT imaging of tumor angiogenesis: quantitative measures describing micromorphology and vascularization | Q37575598 | ||
| Affibody molecules: engineered proteins for therapeutic, diagnostic and biotechnological applications. | Q37730252 | ||
| A systematic review of the factors affecting accuracy of SUV measurements | Q37774810 | ||
| Targeting the epidermal growth factor receptor in solid tumor malignancies. | Q37990044 | ||
| The EPR effect for macromolecular drug delivery to solid tumors: Improvement of tumor uptake, lowering of systemic toxicity, and distinct tumor imaging in vivo | Q38054216 | ||
| Imaging EGFR and HER2 by PET and SPECT: a review | Q38137829 | ||
| HER2-positive tumors imaged within 1 hour using a site-specifically 11C-labeled Sel-tagged affibody molecule. | Q39300829 | ||
| Imaging agents for in vivo molecular profiling of disseminated prostate cancer--targeting EGFR receptors in prostate cancer: comparison of cellular processing of [111In]-labeled affibody molecule Z(EGFR:2377) and cetuximab. | Q39604879 | ||
| Studies on renal tubular protein reabsorption: Partial and near complete inhibition by certain amino acids | Q39615768 | ||
| Small-animal PET imaging of human epidermal growth factor receptor positive tumor with a 64Cu labeled affibody protein | Q39713379 | ||
| Imaging of EGFR expression in murine xenografts using site-specifically labelled anti-EGFR 111In-DOTA-Z EGFR:2377 Affibody molecule: aspect of the injected tracer amount | Q39786140 | ||
| PET of EGFR antibody distribution in head and neck squamous cell carcinoma models | Q39838100 | ||
| Affibody molecules for epidermal growth factor receptor targeting in vivo: aspects of dimerization and labeling chemistry | Q39891849 | ||
| Disparity between in vivo EGFR expression and 89Zr-labeled cetuximab uptake assessed with PET. | Q39903960 | ||
| P275 | copyright license | Creative Commons Attribution 4.0 International | Q20007257 |
| P6216 | copyright status | copyrighted | Q50423863 |
| P4510 | describes a project that uses | CellProfiler | Q5058134 |
| P433 | issue | 1 | |
| P304 | page(s) | 58 | |
| P577 | publication date | 2016-07-07 | |
| P1433 | published in | EJNMMI Research | Q27723773 |
| P1476 | title | Preclinical PET imaging of EGFR levels: pairing a targeting with a non-targeting Sel-tagged Affibody-based tracer to estimate the specific uptake | |
| P478 | volume | 6 |
| Q64080497 | Affibody-Based PET Imaging to Guide EGFR-Targeted Cancer Therapy in Head and Neck Squamous Cell Cancer Models |
| Q61809501 | Analysis of Progress and Challenges of EGFR-Targeted Molecular Imaging in Cancer With a Focus on Affibody Molecules |
| Q90581932 | ImmunoPET: Concept, Design, and Applications |
| Q92438418 | Novel EBV LMP-2-affibody and affitoxin in molecular imaging and targeted therapy of nasopharyngeal carcinoma |
Search more.